In vitro pharmacological effects of peficitinib on lymphocyte activation: a potential treatment for systemic sclerosis with JAK inhibitors

OBJECTIVES: Peficitinib, a novel Janus kinase (JAK) inhibitor, demonstrated promising results in treating RA in phase 3 clinical trials. This in vitro study was undertaken to characterize the pharmacological properties of peficitinib and investigate the involvement of JAK and signal transducer and a...

Descripción completa

Detalles Bibliográficos
Autores principales: Kitanaga, Yukihiro, Imamura, Emiko, Nakahara, Yutaka, Fukahori, Hidehiko, Fujii, Yasutomo, Kubo, Satoshi, Nakayamada, Shingo, Tanaka, Yoshiya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7382595/
https://www.ncbi.nlm.nih.gov/pubmed/31764973
http://dx.doi.org/10.1093/rheumatology/kez526

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7382595/
https://www.ncbi.nlm.nih.gov/pubmed/31764973
http://dx.doi.org/10.1093/rheumatology/kez526

Ejemplares similares